Original Research
Published on 27 Oct 2023
Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study
in Transplantation Immunology
![Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study](https://www.frontiersin.org/files/myhome article library/1264903/1264903_Thumb_400.jpg)
- 1,195 views
- 1 citation